Previous 10 | Next 10 |
Carbonite (NASDAQ: CARB ) +25% on being acquired for $1.42B. More news on: Carbonite, Inc., Qurate Retail, Inc., Assembly Biosciences, Inc., Stocks on the move, Read more ...
ABI-H0731 + nucleos(t)ide analogs (Nrtl) in patients with chronic Hepatitis B demonstrated favorable longer-term tolerability, greater reductions in HBV DNA and HBV pregenomic (pg) RNA in Phase 2 studies than Nrtl alone Significant declines in HBV pgRNA, a surrogate marker of cccDNA, ...
Assembly Biosciences (NASDAQ: ASMB ): Q3 GAAP EPS of -$0.96 misses by $0.03 . More news on: Assembly Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif.,, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial result...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment ...
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of induc...
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment ...
Big pharma money at risk The nonpartisan congressional budget office ((CBO)) analyzed house speaker Nancy Pelosi's (D-CA 12th District) bill to lower drug prices and found that Medicare could save $345 billion between 2023 and 2029. That is more than the GDP of 90% of all countries. The ...
The American Association of Liver Diseases Annual Meeting, better known as The Liver Meeting, will open in Boston on Nov. 8. Data will be presented on new therapies for diseases ranging from hepatitis to non-alcoholic steatohepatitis (NASH), which affect hundreds of thousands, if not millions, o...
News, Short Squeeze, Breakout and More Instantly...
Assembly Biosciences Inc. Company Name:
ASMB Stock Symbol:
NASDAQ Market:
Assembly Biosciences Inc. Website:
2024-07-16 14:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– Data from both ABI-5366 and ABI-1179, novel long-acting helicase-primase inhibitor candidates for recurrent genital herpes, to be presented – – Poster presentation highlights key preclinical data from ABI-5366 supporting its entry into ongoing Phase 1a/b clinical ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a nex...